Tackling the global diabetes burden: Will screening help?

The Lancet

Volumn 380, Issue 9855, 2012, Pages 1716-1718

  Engelgau, Michael M ^a   Gregg, Edward W ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIETY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COST; DEPRESSION; FOLLOW UP; GENERAL PRACTICE; GLYCEMIC CONTROL; HEALTH CARE; HYPERTENSION; MORBIDITY; MORTALITY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RISK; RISK FACTOR; RISK REDUCTION; SCREENING; UNITED KINGDOM;

EID: 84869092514     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61682-1     Document Type: Note

References (15)

1. Danaei G, Finucane MM, Lu Y, et al, on behalf of the Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 2011; 378: 31-40.
2. Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010; 362: 1090-101.
3. Simmons RK, Echouffo-Tcheugui JB, Griffin SJ. Screening for type 2 diabetes: an update of the evidence. Diabetes Obes Metab 2010; 12: 838-44.
4. Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet 2012; published online Oct 4. http://dx.doi.org/10.1016/S0140-6736(12)61422-6.
5. Griffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet 2011; 378: 156-67.
6. Eborall HC, Griffin SJ, Prevost AT, Kinmonth AL, French DP, Sutton S. Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ 2007; 335: 486.
7. Mai KS, Sandbaek A, Borch-Johnsen K, Lauritzen T. Are lifestyle changes achieved after participation in a screening programme for type 2 diabetes? The ADDITION Study, Denmark. Diabet Med 2007; 24: 1121-28.
8. Engelgau MM. Trying to predict the future for people with diabetes: a tough but important task. Ann Intern Med 2005; 143: 301-02.
9. Kahn R, Alperin P, Eddy D, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 2010; 375: 1365-74.
10. Norris SL, Kansagara D, Bougatsos C, Fu R. Screening adults for type 2 diabetes: a review of the evidence for the US Preventive Services Task Force. Ann Intern Med 2008; 148: 855-68.
11. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care 2011; 34 (suppl 1): S11-61.
12. WHO. Screening for type 2 diabetes. Geneva: World Health Organization, 2003.
13. Chatterton H, Younger T, Fischer A, Khunti K. Risk identification and interventions to prevent type 2 diabetes in adults at high risk: summary of NICE guidance. BMJ 2012; 345: e4624.
14. Gillies CL, Lambert PC, Abrams KR, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ 2008; 336: 1180-85.
15. Uusitupa M, Peltonen M, Lindstrom J, et al. Ten-year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study - secondary analysis of the randomized trial. PLoS One 2009; 4: e5656.